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Summary
What is already known on this topic?
Trans-fatty acid (TFA) intake increases the risk of morbidity and mortality
due to coronary heart disease and all-cause mortality. Many low- and
middle-income countries lack accurate and reliable data on TFA intake in
their populations.
What is added by this report?
We found wide variations in global burden of TFA intake. TFA intake and
TFA-attributed cardiovascular disease has decreased in high-income coun-
tries. An urgent need exists to measure and monitor TFA intake globally.
Human biological tissues can be used as biomarkers of TFAs as they re-
flect actual intake from various foods.
What are the implications for public health practice?
Laboratory testing of TFA levels in plasma or serum is a direct and reliable
method for estimating short-term TFA intake from foods. Measuring and
monitoring TFA intake in the population is key for making evidence-based
policies and evaluating the effectiveness of public health interventions.
Abstract
Trans-fatty acid (TFA) intake can increase the risk of coronary
heart disease (CHD) morbidity and mortality and all-cause mortal-
ity. Industrially produced TFAs and ruminant TFAs are the major
sources in foods. TFA intake and TFA-attributed CHD mortality
vary widely worldwide. Excessive TFA intake is a health threat in
high-income countries; however, it  is also a threat in low- and
middle-income countries (LMICs). Data on TFA intake are scarce
in many LMICs and an urgent need exists to monitor TFAs glob-
ally. We reviewed global TFA intake and TFA-attributed CHD
mortality  and current  progress  toward policy or  regulation on
elimination of industrially produced TFAs in foods worldwide.
Human biological tissues can be used as biomarkers of TFAs be-
cause they reflect actual intake from various foods. Measuring
blood TFA levels is a direct and reliable method to quantify TFA
intake.
Background
The World Health Organization (WHO) calls for elimination of in-
dustrially produced (artificial) trans-fatty acids (TFAs) from the
global food supply by 2023; in May 2018 WHO launched the RE-
PLACE (review, promote, legislate, assess, create, enforce) action
package to provide strategic guidance for all countries to take ac-
tion toward this goal (1).  One of the 6 components of the RE-
PLACE package is to “assess and monitor trans-fats content in the
food supply and changes in trans-fat consumption in the popula-
tion.” Measuring the TFA levels in human biologic tissues can be
an objective and reliable method for quantifying total TFA intake
from foods (2–4). TFAs are derived from 2 major sources: indus-
trially produced TFAs (iTFAs) and ruminant TFAs (rTFAs). Par-
tially hydrogenated oils are the primary sources of iTFAs and are
found in margarines, shortenings, baked goods, some popular pro-
cessed and frozen foods (microwave popcorn, frozen pizza, snack
foods), and fried foods (5). Dairy products and meats of ruminant
animals (eg, cattle, sheep, goats) may contain small quantities of
rTFAs. Both iTFAs and rTFAs consist of the same positional trans
isomers, but they differ in distribution and amount. The number of
calories in iTFAs as a proportion of the number of calories in all
TFAs in the daily diet varies across countries; this proportion is
estimated to range from 20% to 80% (5). In practice, because it is
difficult to distinguish between iTFAs and rTFAs in human biolo-
gic tissues, total TFAs are quantified.
Evidence from experimental studies, dietary trials, and prospect-
ive observational studies in which TFAs are measured by bio-
markers or dietary records consistently shows that intake of TFAs,
from either industrial or natural sources, can increase low-density
lipoprotein (“bad”) cholesterol levels, decrease high-density lipo-
protein (“good”) cholesterol levels, and is associated with an in-
creased risk of coronary heart disease (CHD) morbidity and mor-
tality and all-cause mortality (6,7). Daily intake of total TFAs var-
ies worldwide; the estimated contribution to total energy intake
ranges  from 0.2% in  Barbados  to  6.5% in  Egypt.  Even  small
amounts of TFAs can contribute to increased risk of CHD (8).
Every year, more than a half-million deaths from CHD worldwide
may be attributable to high intake of TFAs (defined by Wang et al
[8] as >0.5% of total energy intake); most of these deaths occur in
low- and middle-income countries (LMICs) (8). Based on data
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published by the Global Burden of Diseases Nutrition and Chron-
ic Diseases Expert Group (8) and application of the Pareto prin-
ciple (9), 15 countries account for approximately 80% of the total
number of CHD deaths attributable to high intake of TFAs glob-
ally (Figure 1).
Figure 1. Pareto analysis on the estimated number of deaths from coronary
heart disease attributable to high intake of trans-fatty acids (TFAs) (defined by
Wang et al  [8] as >0.5% of total  energy intake),  top 30 countries.  Pareto
charts are used to describe the countries in descending order of the total
estimated number of CHD deaths worldwide (9). In this chart, bars indicate
the estimated number of CHD deaths attributable to high TFA intake, the
curved line indicates cumulative percentages, and the dashed line indicates
the 15 countries that account for 80% of total CHD deaths attributable to high
TFA intake worldwide according to the Pareto principle (the 80/20 rule). Data
source: Wang et al (8).
Progress Toward Reduction of TFA
Intake
The harmful health effects of TFAs, combined with high levels of
iTFA intake, have motivated policy makers in many countries to
take action. In the past 15 years, progress has been made toward
reducing iTFA intake (10–13). In 2003, Denmark was the first
country to enact  a law to restrict  the iTFA content  of  all  food
products and ready-to-eat meals, requiring that no more than 2%
of the total fat content could come from iTFAs (10). Canada and
the United States, where the daily dietary intakes of TFAs were
more than twice the WHO-recommended limit of 1% of energy in-
take (5), were among the first countries to introduce mandatory la-
beling of TFAs in packaged foods in 2003; mandatory labeling
went into effect in Canada in 2005 and the United States in 2006
(11,12). In the absence of national restrictions, numerous local jur-
isdictions in the United States, such as New York City, restricted
TFAs in food service establishments, including restaurants, cater-
ers, mobile food-vending units, and mobile food commissaries
(13). In recent years, both the United States and Canada used ex-
isting food additive regulations to issue determinations that par-
tially hydrogenated oils are not generally recognized as safe for
any use in human foods, becoming the first countries to effect-
ively ban iTFAs (11,12).  To date,  some 40 countries,  most  of
which are high-income or upper-middle–income countries, have
adopted mandatory restriction of iTFAs, banned the use of par-
tially hydrogenated oils, and/or required mandatory labeling of
TFAs on packaged foods (Figure 2).
Figure  2.  Countries  with  policies  or  regulations  on  industrially  produced
(artificial) TFAs. Data source: World Health Organization (14). Abbreviation:
PHO, partially hydrogenated oil; TFA, trans-fatty acid.
Reductions in TFA intake, iTFAs in foods, and TFA-attributed
CHD mortality have been reported in the United States, Denmark,
and  Argentina  since  the  implementation  of  TFA  policies
(13,15–20).  In  the  United  States  overall,  from 1999–2000  to
2009–2010, plasma TFA levels decreased by 54% in adults aged
20 or older (15); both TFA food labeling and local regulations
were enacted during this 10-year period. New York City’s 2007
regulation restricting TFAs in food-service establishments was as-
sociated with a significant reduction of 2.4 g in mean TFAs in
fast-food purchases (13) and a greater decline in adult serum TFA
levels  among  frequent  restaurant  diners  (61.6%)  than  among
people who rarely dined out (51.1%) (16). These declines show
how the effect of the regulation in New York City added to the ef-
fect of labeling overall in the United States (16). Cardiovascular
disease mortality was also affected, declining by 4.5% in New
York City (17) and by 22 deaths per 100,000 person-year in Den-
mark (18).  Restaurant restrictions in 11 counties in New York
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State were associated with an additional 6.2% decline, compared
with 25 counties without TFA restrictions, in the hospital admis-
sion rate for myocardial infarction and stroke (19). Similarly, near
elimination of iTFAs in Argentina was associated with a 1.3% to
6.3% reduction in CHD events in 2004 and 2014 (20).
Elimination of iTFAs from the food supply is politically viable,
economically favorable, and technically feasible. Successful ex-
periences in high-income countries such as the United States and
Denmark can be transferred to LMICs. Some LMICs, such as Ar-
gentina, Brazil, Costa Rica, India, and Mexico, have taken steps to
enact policies and/or create surveillance systems for monitoring
TFA  content  in  cooking  oils  and  foods  (21).  However,  most
LMICs  have  no  policies  on  iTFAs  or  have  not  enforced  the
policies they do have, despite the growing burden of CHD.
Making the case to restrict TFAs through regulation or legislation
requires more than just the scientific case against TFAs. Informa-
tion on the level of iTFAs in foods or on TFA intake are critical to
motivate stakeholders and to evaluate the progress of eliminating
partially hydrogenated oils in the food supply. To date, however,
little is known about TFA intake in most LMICs (5), let alone the
potential reduction in CHD burden and health benefits that could
result from the elimination of iTFAs. For example, removal of
partially hydrogenated oils in the United States was estimated to
save $130 billion over 20 years and prevent 3,000 to 7,000 deaths
due to CHD annually (12).
Implications for Public Health Practice
Need for objective and accurate measurement of
TFA intake worldwide
In light of gaps in data on TFA intake, there is an urgent need to
measure and monitor TFA intake globally. The current methods
for estimating TFA intake are difficult to implement in LMICs.
The primary method for estimating TFA intake is to collect data
through food frequency dietary interviews in national health and
nutrition surveys. In these surveys, the quantity of food products
consumed is examined, and the TFA content is analyzed by con-
sulting nutrition databases. Limitations of this method include in-
complete or nonexistent information on TFA content in various
food products and the reliance of dietary questionnaires on parti-
cipant recall. Although it is possible to test popular foods for their
TFA content, this testing is complex because TFA content may
vary across brand (or vendor) and by geographic region. Further-
more, if countries are not already sampling and testing foods for
other nutrients, new surveys would need to be developed and im-
plemented. A second common method for estimating TFA intake
is to survey a small sample of people and test duplicate portions of
their meals for TFAs; this method is costly and complicated. A
fast and effective approach for assessing the effect of policies is to
measure TFA levels in blood. Such data are not currently avail-
able in many countries. The Centers for Disease Control and Pre-
vention (CDC) pioneered a new technique for measuring TFAs in
blood that was used on a subsample of the National Health and
Nutrition Examination Survey in 1999–2000 and 2009–2010, al-
lowing the assessment of change in TFA intake over time (15,22).
Types of biological specimens for measuring TFAs
TFAs in the human body are derived from consumption of foods
that contain TFAs; they cannot be synthesized by the human body.
Therefore, TFA concentrations in human biologic tissues reflect
dietary intake (2). Turnover rates or half-lives of fatty acids vary
greatly from one part of the human body to another (2,3). Adipose
tissue, with a slow turnover (average half-life of approximately 1
or 2 years), can be considered the best choice to assess long-term
intake of TFAs. Red blood cells, with a moderate turnover (aver-
age half-life of approximately 1–4 months), can be used to assess
medium-term intake. Plasma and serum, with a quick turnover
(average half-life of approximately 5–10 days), are best used to as-
sess short-term intake. Although adipose tissue might be ideal for
assessing long-term intake, in practice, this approach is rarely used
in large-scale epidemiologic studies and surveys because of the
difficulty in obtaining samples. Specimens of plasma, serum, and
red blood cells are widely used because of their accessibility; use
of these specimens assumes relatively stable short-term dietary
patterns. The standard laboratory protocol developed by CDC can
be used to measure TFAs in plasma, serum, and red blood cells
(erythrocytes) (22).
Whole blood has been proposed as an alternative specimen, and it
could yield results on TFA intake that are similar to the results ob-
tained by examining plasma (4). Moreover, the use of whole blood
enables microsampling procedures (fingertip prick or heel prick)
to  collect  dried  blood-spot  samples,  which  require  low blood
volume and simplified procedures for handling, storing, and pro-
cessing samples. Indeed, dried blood-spot samples have been used
to test many biomarkers (eg, hemoglobin, vitamin A, HIV) in the
Demographic and Health Surveys Program in more than 50 coun-
tries (23). However, the dried blood-spot method is not widely
used for fatty acid profiling because of its potential limitations
(24). Oxidative degradation and filter paper contamination during
sample storage and processing may compromise the accuracy of
dried blood-spot assays for analyzing fatty acid composition. In
addition,  lack of  consensus in analytic  procedures or  standard
laboratory guidelines and difficulties in measuring fatty acid con-
centrations in the dried blood-spot samples may affect the reliabil-
ity and comparability of laboratory data over time and across dif-
ferent populations.
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Practice of measuring TFAs in LMICs
Measuring TFAs as a part of national surveys in LMICs could be
the most effective and direct way to understand TFA intake. Many
LMICs collect blood samples (plasma or serum) as part of their
national  health  or  nutrition  surveys,  so  it  would  be  relatively
simple to include TFA biomarkers as an additional test. The World
Health Organization’s STEPwise Approach to Surveillance uses
blood samples to test for cholesterol and blood glucose levels; this
simple, standardized method for collecting, analyzing, and dissem-
inating data has been implemented in more than 100 countries
(25). National and regional laboratories would need to establish
and build the technical and scientific capacity for measuring TFAs
in blood and in foods. These laboratory measurements are com-
plex and require a high-quality system to ensure accuracy and reli-
ability of data over time and across countries and regions. High-
quality systems would need to include common and standardized
measurement protocols, training of personnel, and external qual-
ity assessment conducted within a network of laboratories. The
data obtained from these laboratories would lead to the establish-
ment of baseline levels of TFA intake, provide scientific evidence
of the effect of public health policy making, and help with direct-
ing further actions to eliminate iTFAs in the food supply. With
surveys and laboratories adhering to the same standards and using
the same high-quality system, data can be compared with global
references  and across  countries.  Because  laboratory  measure-
ments of TFAs also enable the measurement of other fatty acids,
building laboratory capacity for measuring TFAs and other bio-
markers for cardiovascular disease risk factors in blood enables
countries and regions to address public health issues beyond iTFA
reduction. Improving cardiovascular health through reduction of
iTFA intake is feasible through shared experience, technical assist-
ance, and advanced laboratory technology. It can be achieved by
collaborating and partnering with key stakeholders in LMICs, and
with public and private partners internationally.
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